Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251306 | 0.93 | DRD4 (0.46) | DRD4DRD2CACNA1GHSD17B10LMNA | |
| SCHEMBL4246918 | 0.89 | CACNA1G (0.41) | DRD4DRD2CACNA1GHSD17B10HTR7 | |
| SCHEMBL4252512 | 0.84 | CACNA1G (0.51) | DRD4DRD2CACNA1GHSD17B10LMNA | |
| SCHEMBL4249562 | 0.83 | DRD2 (0.46) | DRD4DRD2CACNA1GLMNAALDH1A1 | |
| SCHEMBL5011504 | 0.81 | DRD4 (0.47) | DRD4DRD2CACNA1GLMNASMN1; SMN2 | |
| SCHEMBL4245649 | 0.81 | CACNA1G (0.41) | DRD4DRD2CACNA1GHTR7 | |
| SCHEMBL4246518 | 0.80 | CACNA1G (0.39) | DRD2CACNA1GLMNAPOLBALDH1A1 | |
| SCHEMBL4245856 | 0.79 | CACNA1G (0.48) | DRD4DRD2CACNA1GHTR7ALDH1A1 | |
| SCHEMBL4248331 | 0.78 | HTR1A (0.40) | DRD2LMNASMN1; SMN2POLBALDH1A1 | |
| SCHEMBL4246647 | 0.77 | DRD2 (0.45) | DRD4DRD2CACNA1GHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | claimed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | claimed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | claimed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | claimed |
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | DRD4 2079/4885DRD2 1498/4885CACNA1G 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.